Want to see TSE:RHEL full AI Analyst Report?
Top Page
Red Light Holland
(RHEL)
Select Model
Select Model
Rating:50Neutral
Price Target:
C$0.03
▲(50.00% Upside)
Action:Reiterated
Date:09/29/26
The score is held back primarily by weak financial performance—ongoing operating losses, recurring negative operating/free cash flow, and declining equity. Technicals are moderately supportive with positive MACD and a neutral-to-slightly bullish RSI, but valuation remains constrained by continued losses (negative P/E) and no dividend support.
Positive Factors
Low leverage and sharply reduced debt
Low leverage reduces the company’s exposure to interest costs and refinancing pressure, preserving financial flexibility while it develops its legal psilocybin business. The sharply reduced debt burden also means future funding needs are less likely to be driven by heavy debt servicing.
Negative Factors
Persistent operating and net losses
Large operating and net losses show that the current revenue base does not cover the company’s operating structure and other costs. Until expenses fall or revenue expands materially, continued losses can consume shareholder capital and limit the company’s ability to fund growth internally.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and sharply reduced debt
Low leverage reduces the company’s exposure to interest costs and refinancing pressure, preserving financial flexibility while it develops its legal psilocybin business. The sharply reduced debt burden also means future funding needs are less likely to be driven by heavy debt servicing.
Read all positive factors
Red Light Holland (RHEL) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$18.42M
Dividend YieldN/A
Average Volume (3M)203.78K
Price to Earnings (P/E)―
Beta (1Y)0.48
Revenue Growth-36.49%
EPS Growth-64.44%
CountryCA
Employees104
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.01
Shares Outstanding614,124,760
10 Day Avg. Volume208,004
30 Day Avg. Volume203,778
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)0.87
Price to Sales (P/S)2.48
P/FCF Ratio-4.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Red Light Holland Business Overview & Revenue Model
Company Description
Based in Toronto, Ontario, Red Light Holland Corp. is primarily involved in the cultivation, production, and retail of recreational magic truffles for the Dutch market. Beyond its own cultivated offerings, the company also engages in the sourcing,...
How the Company Makes Money
Red Light Holland’s primary revenue model is based on selling psilocybin-containing products (notably psilocybin truffles) in jurisdictions where such products are legal for sale, with the Netherlands historically being the key market referenced b...
Red Light Holland Financial Statement Overview
Summary
Income Statement
23
Negative
Balance Sheet
56
Neutral
Cash Flow
27
Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Red Light Holland Technical Analysis
Neutral
0.02
Price Trends
0.03
Positive
0.03
Negative
0.03
Positive
Market Momentum
<0.01
Positive
48.57
Neutral
16.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RHEL, the sentiment is Neutral. The current price of 0.02 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 48.57 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:RHEL.
Red Light Holland Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | C$6.20M | -625.00 | -2.30% | ― | 52.89% | 98.68% | |
53 Neutral | C$4.07B | -75.00 | -4.47% | ― | 1.50% | 81.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$18.42M | -2.07 | -41.33% | ― | -36.49% | -64.44% | |
45 Neutral | C$12.56M | -1.04 | 288.66% | ― | ― | -162.50% | |
44 Neutral | C$103.09M | -1.29 | -285.96% | ― | -7.77% | -52.56% | |
43 Neutral | C$60.36M | -0.60 | -131.41% | ― | -21.90% | -25.05% |
* Healthcare Sector Average
TSE:RHEL
Red Light Holland
0.03
>-0.01
-14.29%
TSE:MUSH
Good Shroom Co Inc
0.13
0.05
66.67%
TSE:RVV
Revive Therapeutics
0.03
0.02
150.00%
TSE:CWEB
Charlotte's Web Holdings
0.39
0.16
71.11%
TSE:CURA
Curaleaf Holdings
14.62
2.32
18.87%
TSE:PLTH
Planet 13 Holdings
0.16
-0.18
-52.94%
Red Light Holland Corporate Events
Business Operations and StrategyM&A TransactionsProduct-Related Announcements
Rhelion Unit Ships Psilocybin Candidate for PTSD Trial in Calgary
Positive
Sep 29, 2026
Rhelion Life Sciences, through its subsidiary Filament Health, has shipped its patented botanical psilocybin candidate PEX010 to the University of Calgary for a Phase 2 clinical trial. The study, known as PsiPTSD, will investigate psilocybin-assis...
Business Operations and StrategyRegulatory Filings and Compliance
Rhelion’s Filament Unit Boosts Psilocybin Supply for Landmark Italian Depression Trial
Positive
Sep 25, 2026
Rhelion Life Sciences, via its subsidiary Filament Health, has expanded its supply and licence agreement with the University G. d’Annunzio of Chieti-Pescara for its psilocybin drug candidate PEX010 in the TEMPO clinical trial for treatment-r...
Business Operations and Strategy
Rhelion Subsidiary Filament Health Wins New Canadian Patent for Natural Psilocybin
Positive
Sep 22, 2026
Rhelion Life Sciences, via its wholly owned subsidiary Filament Health, has secured a new Canadian patent covering psychoactive alkaloid extraction and compositions with controlled dephosphorylation for natural psilocybin. The patent strengthens p...
Business Operations and Strategy
Rhelion Subsidiary Supplies Psilocybin for Phase 3 Palliative Care Trial
Positive
Sep 21, 2026
Rhelion Life Sciences’ subsidiary Filament Health has delivered its standardized botanical psilocybin candidate PEX010 to Bruyère Health Research Institute for a Phase 3, multi-site, placebo-controlled clinical trial in palliative care....
Business Operations and Strategy
Rhelion’s Filament Health inks psilocybin supply deal with Dutch research centre
Positive
Sep 17, 2026
Rhelion Life Sciences, through its wholly owned subsidiary Filament Health, is advancing naturally derived psilocybin-based therapeutics within the legal psychedelic sector. Filament develops and supplies its patented botanical psilocybin drug can...
Business Operations and StrategyProduct-Related Announcements
Rhelion’s Filament Health to Supply Psilocybin Candidate PEX010 for USC Mindfulness Trial
Positive
Sep 16, 2026
Rhelion Life Sciences, via its wholly owned subsidiary Filament Health, operates in the legal psychedelic sector with a focus on developing naturally derived psilocybin therapies. The company leverages Filament’s patented PEX010 drug candida...
Business Operations and StrategyProduct-Related Announcements
Rhelion Unit Filament Ships Psilocybin Drug to Australia for First-of-Its-Kind FND Trial
Positive
Sep 8, 2026
Rhelion Life Sciences, via its wholly owned subsidiary Filament Health, has shipped its patented botanical psilocybin drug candidate PEX010 from Canada to Australia. The product will be used at Austin Health in Melbourne in PSI-PHY, an investigato...
Business Operations and Strategy
Rhelion Subsidiary Ships Psilocybin Candidate to Australia for Novel Movement Disorder Trial
Positive
Sep 8, 2026
Rhelion Life Sciences’ subsidiary Filament Health has exported its patented botanical psilocybin candidate PEX010 from Canada to Australia for the PSI-PHY pilot trial, which will test psilocybin-assisted physiotherapy in adults with refracto...
Business Operations and Strategy
Rhelion Expands Role in EU Psilocybin Access With New PEX010 Delivery to Germany
Positive
Sep 3, 2026
Rhelion Life Sciences, via its subsidiary Filament Health, has completed an additional shipment of its patented, GMP-manufactured botanical psilocybin candidate PEX010 to Germany’s Central Institute of Mental Health. The drug is being used i...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Rhelion Life Sciences Marks Transformational Quarter With Filament Acquisition and Psychedelic Drug Push
Positive
Aug 31, 2026
Rhelion Life Sciences reported results for the first quarter of fiscal 2027, highlighting a transformational period marked by the closing of its acquisition of Filament Health and the launch of a new life sciences platform. The deal shifts Rhelion...
Business Operations and Strategy
Rhelion’s Filament Unit Wins New U.S. Patent, Expanding Natural Psilocybin IP Estate
Positive
Aug 27, 2026
Rhelion Life Sciences, through its subsidiary Filament Health, has strengthened its position in the legal psychedelic drug sector by securing a new United States patent for dephosphorylation-controlled extraction of psychoactive alkaloids. This pa...
Business Operations and StrategyProduct-Related Announcements
Rhelion’s Filament Health Supplies Psilocybin PEX010 for University of Washington Cancer Anxiety Trial
Positive
Aug 25, 2026
Rhelion Life Sciences, through its subsidiary Filament Health, is strengthening its role in the legal psychedelic therapeutics sector by supplying patented botanical psilocybin to research and compassionate use programs worldwide. Its lead drug ca...
Business Operations and Strategy
Rhelion’s Filament Health to Harness FDA-Authorized AI Imaging in Psilocybin Alzheimer’s Trial Design
Positive
Aug 20, 2026
Rhelion Life Sciences’ subsidiary Filament Health has signed a non-binding letter of intent with San Francisco-based Darmiyan to explore integrating Darmiyan’s FDA De Novo authorized BrainSee AI imaging platform into the design of futu...
Business Operations and StrategyExecutive/Board ChangesM&A Transactions
Rhelion Life Sciences Names New CFO as Psychedelic Drug Platform Expands
Positive
Aug 19, 2026
Rhelion Life Sciences, an Ontario-based psychedelic life sciences company, has reshaped its business around pharmaceutical drug development and regulated supply of naturally derived psychedelic medicines following the acquisition of Filament Healt...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.